Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- Characterize the safety and tolerability of IMGN529 in combination with rituximab when administered IV every three weeks to adult patients with relapsed and/or refractory NHL - Determine the anti-tumor activity of IMGN529 in combination with rituximab when administered IV every three weeks to adult patients with relapsed and/or refractory NHL
Critère d'inclusion
- Patients with Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin’s Lymphoma